IPOS-Liver Validation Study
A Longitudinal Observational Psychometric Validation Study of the Integrated Palliative Care Outcome Scale-Liver (IPOS-Liver) in Advanced Chronic Liver Disease.
People with advanced liver disease often experience complex physical symptoms, emotional concerns, and practical difficulties, especially as their illness progresses. Currently, there are no questionnaires designed specifically to capture these needs and experiences. A purposely designed questionnaire could help healthcare professionals better understand patients' needs and improve the care they receive. The questionnaire must be tested to make sure that it is reliable, accurate and acceptable to patients. This process is known as validation.
This study is testing a new questionnaire called the Integrated Palliative care Outcome Scale- Liver (IPOS-Liver). It asks about symptoms and concerns experienced by people living with advanced liver disease.
The study will take place in two NHS hospitals in England. 71 NHS patients with advanced chronic liver disease will take part, together with healthcare professionals involved in their care. Patients and healthcare professionals will be asked to complete the IPOS-Liver questionnaire alongside other established questionnaires. These will be completed at two time points a few days apart. The results will be statistically analysed to see whether the new questionnaire gives consistent and useful results. A small number of patients will additionally be invited to take part in a 30-minute interview about their experience of completing the IPOS-Liver. Adult NHS patients in England will be invited to take part after the clinician caring for them identifies that they are eligible for the study.
연구 개요
상태
상태
정황
정황
상세 설명
This multi location, longitudinal, observational mixed methods study will evaluate the psychometric properties of the Integrated Palliative Care Outcome Scale-Liver (IPOS Liver). The IPOS Liver is a newly developed patient reported outcome measure within the IPOS family, designed to capture symptoms, concerns, and unmet palliative care needs specific to people with advanced chronic liver disease (ACLD). Existing outcome measures do not fully reflect the unique palliative symptoms experienced by this population.
The IPOS Liver was developed in collaboration with a patient and public involvement and engagement (PPIE) group and an expert panel comprising hepatology and palliative care clinicians. This study will assess the measure's psychometric properties in 71 adults with ACLD receiving care in hospitals, hospices, or outpatient settings across England using a consecutive eligibility sampling strategy.
Validity and reliability will be examined through correlations between IPOS Liver scores and established clinical outcome measures, assessment of change in IPOS Liver scores over two time points, and evaluation of whether IPOS-Liver score changes correspond with clinical change. In addition, the views and experiences of using the IPOS Liver will be explored through qualitative interviews with a purposively sampled subgroup of patients and healthcare professionals to further support content validity.
The study will be conducted in two locations in England and will be supported by clinicians affiliated with the British Association for the Study of the Liver (BASL) Palliative Hepatology Specialist Interest Group. Ethical safeguards including on-going capacity assessments to ensure decision-specific consent and the right to withdraw with full data deletion, will protect vulnerable participants. Findings from this 18 month study will determine whether the IPOS Liver is a reliable and valid outcome measure suitable for use in clinical practice and research involving people with ACLD
연구 유형
연구 유형
등록 (추정된)
등록
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Patients at participating locations.
설명
Inclusion Criteria:
-
Live in England
-
Have capacity to give written informed consent to participate in the study, as judged by the clinical team
-
The patient is able to communicate and understand English adequately to complete the IPOS-Liver and provide informed consent (NHS translation services and reading of research documents will be used to support participation for those with limited English or literacy when feasible)
-
Have a diagnosis of ACLD from any underlying aetiology, with at least one of the following clinical scores:
- Child-Pugh B9
- UKELD 49
- BCLC stage C
-
Is expected to be reviewed on two occasions within 5 days as an inpatient, or is being cared for as an outpatient.
Exclusion Criteria:
- Patients without capacity to consent as judged by the clinical team
- Patients currently too symptomatic or distressed to participate, as judged by the clinical team
- Patients unable to understand written and verbal communication in English
Staff members caring for patients will also become participants in the study.
Staff-participant inclusion criteria are:
- Be a healthcare professional involved with the care of a participant enrolled in the study
- Have authorised access to the participant's medical notes
- Give consent to be involved in the study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: OTHER
- 시간 관점: OTHER
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Construct Validity
기간: Up to 21 days
|
Construct validity establishes the theoretical relationship between variables on the new IPOS-Liver and those on established measures of the same construct and scores between sub-groups of participants (DeVellis & Thorpe, 2022). This will be established by exploring convergent and divergent validity as well as known group comparisons. |
Up to 21 days
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Internal consistency
기간: Up to 21 days
|
Internal consistency reflects how closely items on the IPOS-Liver are related, or measure the same underlying construct. |
Up to 21 days
|
|
Inter-rater reliability
기간: Up to 21 days
|
Inter-rater reliability is the degree of agreement between different raters using the IPOS-Liver. |
Up to 21 days
|
|
Content and face validity
기간: Up to 21 days
|
The extent to which items reflect the construct being measured. |
Up to 21 days
|
|
Floor and ceiling effects
기간: Up to 21 days
|
The percentage of participants (staff or patients) who have either maximum or minimum IPOS-Liver scores will be calculated. |
Up to 21 days
|
공동 작업자 및 조사자
협력자
협력자
간행물 및 유용한 링크
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
기타 연구 ID 번호
- 372666
- 26/EE/0195 (기타 식별자: REC reference)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Participants will be informed that only anonymised data may be shared with other researchers (i.e. the data set will be shared, but the consent forms linking the name and study identification number will not be shared), this will be facilitated through depositing the data in the University of Hull's Repository.
IPD 공유 기간
From completion of the study (2028-2029) for 5 years.
IPD 공유 액세스 기준
Ethically-approved academic and medical research projects in the UK and European Union that have an adequacy decision in place, equivalent data security measures and valid data sharing contracts (in accordance with UK GDPR) will be able to access the fully-anonymised data set.
IPD 공유 지원 정보 유형
- ANALYTIC_CODE
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .